Table 1.
Clinical characteristics of patients with non-lepidic and lepidic NSCLC who underwent sublobar resection or lobectomy
| Characteristic | Non-lepidic NSCLC | Lepidic NSCLC | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Sublobar resection (n=60) | Lobectomy (n=131) | p-value | Sublobar resection (n=50) | Lobectomy (n=87) | p-value | |
| Age (yr) | 65.5±11.7 | 62.7±11.0 | 0.103 | 60.1±12.3 | 59.9±8.4 | 0.913 |
|
| ||||||
| Gender | 0.523 | |||||
|
| ||||||
| Male | 30 (50.0) | 72 (55.0) | 21 (42.0) | 29 (33.3) | ||
|
| ||||||
| Female | 30 (50.0) | 59 (45.0) | 29 (58.0) | 58 (66.7) | 0.310 | |
|
| ||||||
| Current or former smoker | 23 (38.3) | 45 (34.4) | 0.594 | 12 (24.0) | 24 (27.6) | 0.646 |
|
| ||||||
| Serum carcinoembryonic antigen level (ng/mL) | 2.3±3.4 | 2.0±1.6 | 0.477 | 1.3±0.9 | 2.2±7.4 | 0.430 |
|
| ||||||
| Maximum standardized uptake value | 2.9±3.0 | 3.7±3.2 | 0.141 | 0.9±1.6 | 1.6±1.9 | 0.060 |
|
| ||||||
| Forced expiratory volume in 1 second (%) | 92.6±18.4 | 100.8±17.7 | 0.004 | 97.8±18.3 | 103.6±15.0 | 0.051 |
|
| ||||||
| Diffusing capacity of the lung for carbon monoxide (%) | 76.6±17.2 | 87.2±19.0 | <0.001 | 84.7±14.7 | 88.9±17.5 | 0.180 |
|
| ||||||
| Tumor location | 0.018 | 1.000 | ||||
|
| ||||||
| Central | 0 | 11 (8.4) | 0 | 1 (1.1) | ||
|
| ||||||
| Peripheral | 60 (100.0) | 120 (91.6) | 50 (100.0) | 86 (98.9) | ||
|
| ||||||
| Clinical stage | 0.463 | 0.415 | ||||
|
| ||||||
| T1aN0M0 | 56 (93.3) | 118 (90.1) | 49 (98.0) | 82 (94.3) | ||
|
| ||||||
| T2aN0M0 | 4 (6.7) | 13 (9.9) | 1 (2.0) | 5 (5.7) | ||
|
| ||||||
| Video-assisted thoracoscopic surgery | 49 (81.7) | 96 (73.3) | 0.208 | 44 (88.0) | 67 (77.0) | 0.114 |
|
| ||||||
| Open thoracotomy | 11 (18.3) | 35 (26.7) | 6 (12.0) | 20 (23.0) | ||
|
| ||||||
| Procedure | ||||||
|
| ||||||
| Wedge resection | 43 (71.7) | 33 (66.0) | ||||
|
| ||||||
| Segmentectomy | 17 (28.3) | 17 (34.0) | ||||
|
| ||||||
| Lobectomy | 129 (98.5) | 85 (97.7) | ||||
|
| ||||||
| Bilobectomy | 2 (1.5) | 2 (2.3) | ||||
|
| ||||||
| Complications | 5 (8.3) | 15 (11.5) | 0.514 | 6 (12.0) | 8 (9.2) | 0.602 |
|
| ||||||
| Postoperative mortality | 0 | 0 | 0 | 0 | ||
|
| ||||||
| Adjuvant therapy | 4 (6.7) | 4 (3.1) | 0.262 | 0 | 0 | |
Values are presented as mean±standard deviation or number (%).
NSCLC, non-small cell lung cancer.